EUROPEAN HEMATOLOGY ASSOCIATION

21st Congress of EHA

 

June 9th - June 12th 2016 Copenhagen
Close
N. Poster
Poster title
Applicant name
Status
  150-P COMPARATIVE ANALYSIS OF GENE REGULATORY NETWORKS IN LYMPHOID LEUKEMIAS USING THE INTERACTIVE HEMAP RESOURCE Juha Mehtonen Received Received
  152-P HEDGEHOG PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PREDICTS RESPONSE TO SMO AND GLI1 INHIBITORS Jolien De Bie Received Received
  153-P IDENTIFICATION OF CANDIDATE ONCOGENES AND CHROMOSOMAL BREAKPOINT SEQUENCING BY TARGETED LOCUS AMPLIFICATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Eric Vroegindeweij Received Received
  154-P A PLATFORM FOR DETECTION OF FUSION GENES IN ALL FROM TARGET CAPTURE NEXT-GENERATION SEQUENCING OF DNA AND RNA. Andrea Grioni Received Received
  155-P THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Marlies Vanden Received Received
  157-P CHARACTERIZATION OF AN EX VIVO T-CELL CULTURE MODEL FOR THE STUDY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Simon Bornschein Bempt Received Received
  160-P DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY. Rajwinder Lehal Bempt Received Received
  162-P LOSS OF PIGH EXPRESSION FREQUENTLY RESULTS IN A GPI-NEGATIVE SUBCLONE LACKING CD52 MEMBRANE EXPRESSION, CONFERRING ALEMTUZUMAB RESISTANCE TO B CELL ACUTE LYMPHOBLASTIC LEUKEMIA Inge JEDEMA Received Received
  164-P BABOON ENVELOPE PSEUDOTYPED LENTIVIRAL VECTORS: A HIGHLY EFFICIENT NEW TOOL TO GENETICALLY MANIPULATE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA INITIATING CELLS Melania TESIO Received Received
  165-P HIGH INCIDENCE OF PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA (PH-LIKE ALL) IN OLDER ADULTS WITH B-ALL Alexander Perl Bempt Received Received
  168-P THE COMBINATION OF BORTEZOMIB AND CHEMOTHERAPY IS AN EFFECTIVE TREATMENT TO RE-INDUCE REMISSION IN RELAPSED/REFRACTORY B-CELL PRECURSOR OR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Alice BERTAINA Bempt Received Received
  169-P EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB VERSUS 1ST- AND 2ND-GENERATION TYROSINE KINASE INHIBITORS FOR PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A META-ANALYSIS AND META-REGRESSION Ariadne Souroutzidis Bempt Received Received
  170-P RISK OF CEREBRAL VEIN THROMBOSIS (CVT) IN ADULT ALL PATIENTS IN FINLAND 1999-2012: SUGGESTION FOR A LEUKEMIA-RELATED PREDICTIVE SCORING MODEL Saara Roininen Received Received
  171-P INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. Nick MORLEY Bempt Received Received
  172-P RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN OLDER/ELDERLY PATIENTS - A SWEDISH POPULATION-BASED STUDY Emma BERGFELT Bempt Received Received
  173-LB N. Toft Received Received
  174-P VENTX INDUCES EXPANSION OF PRIMITIVE ERYTHROID CELLS AND CONTRIBUTES TO THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA IN MICE Eva Gentner Bempt Received Received
  175-P ABNORMAL INTRAGENIC TRANSCRIPTIONAL ACTIVATION IN MLL-AF9 AND KAT6A-CREBBP ACUTE MYELOID LEUKEMIA (AML) Anna Marneth Received Received
  176-P HHEX TRANSFORMS PROMYELOCYTES AND COOPERATES WITH FACTOR INDEPENDENCE TO CAUSE PROMYELOCYTIC LEUKEMIA IN MICE Jacob T Jackson Received Received
  177-P A SOMATIC MUTATION OF GFI1B IDENTIFIED IN LEUKEMIA ALTERS CELL FATE VIA A SPI1 (PU.1) CENTERED GENETIC REGULATORY NETWORK Eduardo Anguita Received Received
  181-P TRIB2 TRANSFORMED GMP AS THE MYELOID LEUKEMIA INITIATING CELL Krishna Yalla Jackson Received Received
  182-P TRIB2 REGULATES THE CELL CYCLE UNDER STRESS CONDITIONS IN A MURINE CELL MODEL OF LEUKEMIA. Mara Salomè Bempt Received Received
  183-P CHROMOTHRIPSIS: A NEW MECHANISM OF CANCER INITIATION AND PROGRESSION IN ADULT ACUTE MYELOID LEUKEMIA Giovanni Martinelli Bempt Received Received
  184-P AN EVALUATION OF THE TYROSINE KINASE INHIBITOR PACRITINIB IN PATIENTS WITH RELAPSED FLT3-MUTATED ACUTE MYELOID LEUKAEMIA (THE UK NCRI AML17 STUDY) Steven Knapper Bempt Received Received
  186-P SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDARUBICIN INDUCTION AND HIGH-DOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED FLT3+ AML Meghan Macaraeg Bempt Received Received
  187-P PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML. Tapan Kadia Received Received
  188-P DIFFERENTIATION RESPONSE TO GILTERITINIB (ASP2215) IN RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA PATIENTS IS ASSOCIATED WITH CO-MUTATIONS IN NPM1 AND DNMT3A Jonathan Canaani Bempt Received Received
  190-P CLINICAL RESPONSE IN RELAPSED/REFRACTORY AML PATIENTS CORRELATES WITH LEUKEMIC BLAST MOBILIZATION AND DIFFERENTIATION INDUCED BY BL-8040, A POTENT CXCR4 ANTAGONIST; RESULTS OF A PHASE IIA STUDY Yaron Pereg Received Received
  193-P A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES Mark Frattini Bempt Received Received
  194-P GENOMIC CHARACTERIZATION OF HIGH-COUNT MBL INDIVIDUALS INDICATES THAT EARLY DETECTION OF DRIVER MUTATIONS AND SUBCLONAL EXPANSION ARE PREDICTORS OF ADVERSE CLINICAL OUTCOME Santiago Barrio Received Received
  195-P IDENTIFICATION OF NOVEL B CELL RECEPTOR ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA Elisa ten Received Received
  198-P IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS OF CHRONIC LYMPHOCYTIC LEUKEMIA Phuong-Hien Nguyen Hacken Received Received
  199-P MICROENVIRONMENTAL STROMAL CELLS TRIGGER HYPOXIA SIGNALLING IN CLL CELLS – A MECHANISM THAT PROVIDES PROTECTION FROM APOPTOSIS AND CAN BE TARGETED THERAPEUTICALLY Daniel Mertens Received Received
  200-P IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS Gabriela Pavlasova Hacken Received Received
  201-P FUNCTIONAL IMPACT OF BONE MARROW MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES ON CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS: APOPTOSIS, MIGRATION, CHEMORESISTANCE AND GENE EXPRESSION MODIFICATION Emerence Crompot Received Received
  202-P THE T-CELL/CLL/MACROPHAGE TRIAD SHAPES A SUPPORTIVE TUMOR MICROENVIRONMENT IN CLL Martijn van Attekum Received Received
  204-P BLOCKING ENDOTHELIN-1 SIGNALING DISRUPTS LEUKEMIC CELL HOMING AND B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA Rossana MAFFEI Attekum Received Received
  205-P GENE EXPRESSION PROFILES OF PERIPHERAL BLOOD T AND NK-CELLS REVEALED DIFFERENT PATTERNS OF IMMUNE DYSFUNCTION IN CLL-LIKE MBL AND EARLY STAGE CLL Anna Puiggros Received Received
  206-P CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION Erika Tissino Attekum Received Received
  210-P PRELIMINARY RESULTS OF A PHASE II STUDY OF IBRUTINIB IN COMBINATION WITH FCR (IFCR) IN PREVIOUSLY UNTREATED, YOUNGER PATIENTS WITH CLL Matthew Davids Received Received
  211-P PRESENCE OF MULTIPLE UNMUTATED IGHV REARRANGEMENTS IN CLL PATIENTS IS ASSOCIATED WITH A VERY SHORT TREATMENT–FREE SURVIVAL: RESULTS FROM 2 INDEPENDENT COHORTS Basile Stamatopoulos Received Received
  212-P NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL Marta Larrayoz Attekum Received Received
  213-P UPDATED RESULTS OF A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IDELALISIB IN COMBINATION WITH OFATUMUMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Timothy Dichiara Attekum Received Received
  218-P ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING FOR THE DETECTION OF SUBCLONAL TP53 ABERRATIONS IN CLL Christian Brieghel Attekum Received Received
  219-P COMPARABLE OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH REDUCED­ DOSE IBRUTINIB: RESULTS FROM A MULTI­-CENTER STUDY Rahul Banerjee Attekum Received Received
  221-P PATIENTS WITH COMPLEX KARYOTYPE (CK) LACKING TP53 DELETIONS SHOW AN EQUIVALENT DISMAL CLINICAL OUTCOME AS THOSE WITH TP53 DELETIONS AND NON-CK IN CHRONIC LYMPHOCYTIC LEUKEMIA Anna Puiggros Attekum Received Received
  230-P IMPACT OF SECOND DECLINE RATE OF BCR-ABL1 TRANSCRIPT BETWEEN M3 AND M6 ON CLINICAL OUTCOME FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB: PRACTICAL ASPECT FOR THE TRUE LIFE Stephanie DULUCQ Attekum Received Received
  232-P LATE RELAPSES, UP TO 45 MONTHS AFTER IMATINIB DISCONTINUATION: RESULTS FROM THE ISAV STUDY Silvia Mori Attekum Received Received
  233-P ASSESSMENT OF THERAPY RESPONSE IN CHRONIC MYELOID LEUKEMIA VIA 1 MONTH BCR-ABL1 TRANSCRIPT DECLINE Mohamed El Missiry Received Received
  234-P DEVELOPMENT AND EVALUATION OF A MR1 – MR4.5 SECONDARY LYOPHILIZED CELL REFERENCE PANEL FOR BCR-ABL1 QUANTIFICATION ON THE INTERNATIONAL SCALE Connie Wong Missiry Received Received
  235-P TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS Carmen FAVA Received Received
  236-P MANAGING CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH HIGH-DOSE IMATINIB. THE ITALIAN EXPERIENCE. Fiorina Giona Attekum Received Received
  238-P VITAMIN C INCREASES VIRAL MIMICRY INDUCED BY 5-AZA-2-DEOXYCYTIDINE Andreas Due Ørskov Received Received
  239-P GENETIC PREDISPOSITIONS TO SPORADIC MYELOID NEOPLASMS CAUSED BY GERMLINE DDX41 MUTATIONS IN ASIAN AND CAUCASIAN POPULATIONS. June Takeda Ørskov Received Received
  240-P IDENTIFICATION OF ALTERED AND CRYPTIC-SPLICING IN SF3B1 MUTANT MYELODYSPLASTIC SYNDROMES AND ISOGENIC MODELS OF SF3B1-K700E MUTATION Fabio Liberante Received Received
  241-P IMPACT OF SOMATIC MUTATIONS ON OUTCOME IN PATIENTS WITH MDS AFTER STEM-CELL TRANSPLANTATION Tetsuichi Yoshizato Received Received
  242-P 17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE Roxana Schaab Ørskov Received Received
  243-P TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS M Teresa Cedena Received Received
  244-P AZACYTIDINE RESTORES THE ABNORMAL STAT SIGNALING BIOSIGNATURE OF FOXP3+ T REGULATORY CELLS (TREGS) IN RESPONDING MDS PATIENTS. Ioannis KOTSIANIDIS Received Received
  245-P A CULTURE MODEL MIMICKING THE BM-NICHE ALLOWS FOR STUDYING THE DYSREGULATED ERYTHROPOIESIS OF SF3B1 MUTATED MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS Edda María Elvarsdóttir Received Received
  246-P THE INCIDENCE AND CLINICAL IMPLICATIONS OF CHROMOTHRIPSIS IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) Zuzana Zemanova Received Received
  247-P MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS. Magnus Tobiasson Elvarsdóttir Received Received
  248-P RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING EPOETIN ALFA VERSUS PLACEBO IN ANEMIC PATIENTS WITH IPSS LOW- INT1 RISK MDS Wayne Elwood Received Received
  250-P MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE Lo-Ho Chen Elvarsdóttir Received Received
  252-P CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q) Guillermo Garcia-Manero Elvarsdóttir Received Received
  254-P THE USE OF A HIGH DENSITY, 2.6 MILLION MARKER, SNP ARRAY AS THE PRIMARY GENETIC TEST FOR MYELODYSPLASTIC SYNDROME AT DIAGNOSIS: INTERIM FINDINGS OF THE WEST MIDLANDS, UK STUDY Nicola Trim Elvarsdóttir Received Received
  257-P FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA OF UNDETERMINED SIGNIFICANCE: ASSOCIATION WITH RISK OF PROGRESSION TO MYELODYSPLASTIC SYNDROME Jakob Werner Hansen Received Received
  258-P MOLECULAR AND CLINICAL TYPES OF PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH DISTINCT EXPRESSION PATTERNS OF LONG NONCODING RNAS Martina Manzoni Hansen Received Received
  259-P RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE Isabel Hofman Hansen Received Received
  260-P COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA WITH A DELETION OF CHROMOSOME 17P REVEALS A HIGH PREVALENCE OF SOMATIC TP53 MUTATIONS, WHICH CORRELATE WITH A POOR PROGNOSIS Davine Hofste op Received Received
  261-P DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY Nicola GIULIANI Received Received
  262-P LOSS OF PRIMING OR MCL-1 DEPENDENCY CONFERRED ACQUIRED RESISTANCE TO VENETOCLAX IN MULTIPLE MYELOMA Martine Amiot op Received Received
  263-P LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA Ester Lozano op Received Received
  264-P PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOWERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE ARREST Sabrina Manni Received Received
  265-P QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR IMPACT ON PATIENT SURVIVAL Irena Misiewicz-Krzeminska op Received Received
  266-P DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS Kohichi Takada op Received Received
  267-P DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR DIAGNOSTIC SERVICE Piers Blombery Received Received
  276-P THE SKY92 PROGNOSTIC MARKER IS VALIDATED IN EIGHT MULTIPLE MYELOMA CLINICAL DATASETS Martin Van Vliet Received Received
  279-P MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA STUDY Marc Raab Vliet Received Received
  281-P FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM) Eva Nordström Received Received
  282-P PRECISION AS PART OF THE ANALYTICAL VALIDATION OF THE SKY92 HIGH RISK SIGNATURE AND THE MMPROFILER ASSAY Martin Van Vliet Received Received
  283-P RISK STRATIFICATION BY SKY92+ISS OUTPERFORMS IFISH MARKERS T(4;14) AND DEL(17P) IN MULTIPLE MYELOMA Martin Van Vliet Received Received
  284-P CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS Dimitrios Christoulas Vliet Received Received
  285-P LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT Dimitrios Christoulas Vliet Received Received
  287-P CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING SYNERGISTIC ACTIVITY IN MPN MODELS Manjola Balliu Vliet Received Received
  290-P LNK MUTATIONS IN FAMILIAL MYELOPROLIFERATIVE NEOPLASMS Elisa Rumi Received Received
  291-P HOMOZYGOUS CALRETICULIN MUTATIONS IN PATIENTS WITH MYELOFIBROSIS LEAD TO ACQUIRED MYELOPEROXIDASE DEFICIENCY Alexandre THEOCHARIDES Vliet Received Received
  293-P MESENCHYMAL STROMAL CELLS (MSC) FROM HIGH-GRADE BONE MARROW FIBROSIS PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (PH-NEG MPN) DISPLAY REDUCED CLONOGENICITY AND PROLIFERATION CAPACITY. Benedetta RAMBALDI Vliet Received Received
  294-P NEXT-GENERATION SEQUENCING IDENTIFIES MPL-TET2 MUTATED CLONES IN A SUBSET OF PATIENTS WITH JAK2V617F-POSITIVE MYELOFIBROSIS Haifa Kathrin AL-ALI Received Received
  297-LB Christian Pecquet Received Received
  298-P CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST CELL DISEASE. Carlos Fernandez Received Received
  299-P MUTATIONAL STUDY OF GENES INVOLVED IN MYELOFIBROSIS BY MASSIVE SEQUENCING Ana Africa Martin Received Received
  301-P PREVENTION OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH HYDROXUYUREA PLUS PHLEBOTOMIES OR HYDROXYUREA ALONE Alberto Alvarez-Larrán Received Received
  302-P RATE OF MALIGNANT TRANSFORMATION IN HIGH RISK ET DURING 5 YEARS OF FOLLOW-UP OF CYTOREDUCTIVE THERAPY Gunnar BIRGEGÅRD Martin Received Received
  304-LB C. Harrison Received Received
  309-P THE LYMPHOMA ASSOCIATED MACROPHAGES-HODGKIN/REED-STERNBERG CELLS RATIO IS A POOR PROGNOSTIC FACTOR IN CLASSIC HODGKIN LYMPHOMA PATIENTS Vit Prochazka Received Received
  310-P THE PROGNOSTIC ROLE OF BCL-2 EXPRESSION IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ASSESSED FOR CD68+ CELL COUNT. Annarosa cuccaro Martin Received Received
  312-P BIOLOGICALLY MEANINGFUL CHANGES IN CYTOKINE AND CHEMOKINE PRODUCTION FOLLOWING IBRUTINIB THERAPY IN WALDENSTROM´S MACROGLOBULINEMIA. Josephine VOS Martin Received Received
  316-P THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED / REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY Constantine Tam Martin Received Received
  318-P PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA Dennis Healy Martin Received Received
  320-P SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) Caterina Cecchetti Martin Received Received
  322-P TO SCREEN BIOLOGICAL MARKER GENE ASSOCIATED WITH B CELL IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) PATIENTS Depei Wu Martin Received Received
  324-P MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS Mette Hazenberg Martin Received Received
  325-P GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION INCREASES THE PROPORTION OF REGULATORY GAMMA DELT T CELLS Qifa Liu Received Received
  326-P PREACTIVATED MESENCHYMAL STROMAL CELLS IMPROVE T-CELL REGENERATION AFTER THEIR COTRANSPLANTATION WITH HEMATOPOIETIC STEM CELLS Selim Kuci Received Received
  327-P EVIDENCE OF COMPLEMENT DYSREGULATION IN TRANSPLANT – ASSOCIATED THROMBOTIC MICROANGIOPATHY Eleni Gavriilaki Received Received
  328-P FAMILY-DIRECTED CORD BLOOD BANKING FOR SICKLE CELL DISEASE: A 20-YEAR EXPERIENCE, ON BEHALF OF EUROCORD-MONACORD AND THE INTERNATIONAL SICKLE CELL DISEASE OBSERVATORY. Hanadi Rafii Martin Received Received
  329-P CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1 AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING Aniko Szabo Martin Received Received
  330-P RELAPSED/REFRACTORY HIGH GRADE B CELL NON-HODGKIN LYMPHOMA: SHOULD ONGOING PET POSITIVITY PRECLUDE AUTOLOGOUS TRANSPLANTATION IN PATIENTS ATTAINING A CT RESPONSE TO SALVAGE CHEMOTHERAPY? Nagah Elmusharaf Martin Received Received
  331-P MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Alex Ganetsky Martin Received Received
  332-P HYPERACUTE GRAFT VERSUS HOST DISEASE: RISK FACTORS, OUTCOMES AND IMPACT OF TACROLIMUS/SIROLIMUS PROPHYLAXIS. Oriana Lopez Received Received
  333-P REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080) Simon Rule Received Received
  334-P THE ROLL OF HYPOMETHYLATING AGENTS IN MYELOID RELAPSES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT. Félix López Cadenas Received Received
  335-P IMPROVED CLINICAL OUTCOMES OF GBM/GPB MIXTURE HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO A PROPENSITY SCORE-MATCHED GPB HAPLOIDENTICAL TRANSPLANTATION: A MULTICENTER STUDY Xiangyu zhao Received Received
  336-P TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION Lotte VAN Received Received
  337-P FIRST-LINE EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR ACUTE GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Andrea RIMONDO Godino Received Received
  338-P EFFICACY OF HOST-DENDRITIC CELL VACCINATIONS WITH AND WITHOUT MINOR HISTOCOMPATIBILITY ANTIGEN LOADING, COMBINED WITH DONOR LYMPHOCYTE INFUSION IN MULTIPLE MYELOMA PATIENTS Rimke Oostvogels DER Received Received
  339-P TRACING OF URINARY EXCRETION OF BKV AND JCV BY QUANTITATIVE PCR IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (ALLO-HSCT) TO ANTICIPATE THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS (HC). Joud Zanabili Al-Sibai Received Received
  340-P OUTCOMES AFTER AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH MYC/BCL2 CO-EXPRESSION, DOUBLE-HIT LYMPHOMA, OR MYC COPY GAIN Alex Herrera Al-Sibai Received Received
  341-P BTLA GENOTYPE AND CLINICAL OUTCOME AFTER HLA-IDENTICAL SIBLING STEM CELL TRANSPLANTATION Nazly Santos Al-Sibai Received Received
  342-P HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN´S LYMPHOMAS (NHL) Samer Srour Al-Sibai Received Received
  345-P HIGH DOSE CHEMOTHERAPY WITH AUTOGRAFT MAY IMPROVE THE POOR PROGNOSIS OF NAIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH MYC/BCL2 CO-EXPRESSION Francesco Maura Al-Sibai Received Received
  346-P BIOMARKERS PREDICTING ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY IN 120 PATIENTS Linda Cheyenne Received Received
  348-P TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONOR IN PEDIATRIC SEVERE APLASTIC ANEMIA: EXPERIENCE WITH TCR ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING METHOD. Daria SHASHELEVA Vaccari Received Received
  350-P HHEX PROMOTES HSC SELF-RENEWAL AND STRESS HEMATOPOIESIS VIA REPRESSION OF CDKN2A Jacob T Jackson Received Received
  352-P NPM1 IS REQUIRED FOR NORMAL HEMATOPOIESIS Chow Hiang Ang Received Received
  353-P PLZF MUTATION ALTERS MOUSE HEMATOPOIETIC STEM CELL FUNCTION AND CELL CYCLE PROGRESSION Christelle VINCENT-FABERT Ang Received Received
  354-P IL-1 INDUCED ACTIVATION OF QUIESCENT HEMATOPOIETIC STEM CELLS IN VIVO Uta Demel Vaccari Received Received
  356-P CLEC-2 EXPRESSION IS A NEW MARKER FOR A SUBSET OF HEMATOPOIETIC STEM/PROGENITOR CELLS THAT CONTRIBUTES TO INFLAMMATION-INDUCED EMERGENT MEGAKARYOPOIESIS Takahiro Kumode Vaccari Received Received
  357-P IN VITRO AND IN VIVO STEM CELL PROPERTIES OF HIGHLY ENRICHED HUMAN BONE MARROW MESENCHYMAL STROMAL CELLS Roshanak Ghazanfari Received Received
  358-P GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS Anindita Roy Vaccari Received Received
  359-P GPR56: A NOVEL MOLECULE INVOLVED IN HEMATOPOIETIC STEM CELL GENERATION Emma DE PATER Received Received
  364-P CORD BLOOD DERIVED NK CELLS TRANSFER HISTONE H2AZ TO MULTIPLE MYELOMA CELLS CAUSING DIRECT AND INDIRECT CYTOTOXICITY Beatriz Martín-Antonio PATER Received Received
  365-P ALLOGENEIC TCRA/CD38 DOUBLE KNOCKOUT T-CELLS BEARING AN ANTI-CD38 CHIMERIC ANTIGEN RECEPTOR: AN IMPROVED IMMUNOTHERAPY FOR THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MULTIPLE MYELOMA. Mathilde Dusseaux PATER Received Received
  366-P OPTIMIZED AAV-MEDIATED HUMAN FACTOR VIII GENE THERAPY IN HEMOPHILIA A MICE AND CYNOMOLGUS MACAQUES James Wilson PATER Received Received
  367-P A DOSE-ESCALATING PRECLINICAL STUDY TO DETERMINE THE SAFETY, EFFICACY, AND MINIMUM EFFECTIVE DOSE OF A CLINICAL CANDIDATE VECTOR IN A MOUSE MODEL OF HEMOPHILIA B James Wilson PATER Received Received
  368-P THE LCR-FREE GAMMA-GLOBIN LENTIVIRAL VECTOR COMBINING TWO HPFH ACTIVATING ELEMENTS CORRECTS MURINE THALASSEMIC PHENOTYPE IN VIVO Nicholas Anagnou Received Received
  369-P BALANCE OF ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING AFFINITY AND DENSITY IN AN IN VITRO MODEL OF ACUTE MYELOID LEUKEMIA Silvia Arcangeli Received Received
  370-P PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS Mira Patel PATER Received Received
  372-P CEREBROVASCULAR RESERVE IN SICKLE CELL DISEASE ASSESSED WITH PERFUSION MAGNETIC RESONANCE IMAGING Lena Vaclavu Received Received
  373-P RESTING STATE FUNCTIONAL MRI SHOWS HOW COGNITIVE PERFORMANCES COULD BE PRESERVED IN CHILDREN WITH SICKLE CELL DISEASE Raffaella Colombatti PATER Received Received
  377-P ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND HOSPITAL ADMISSIONS FOR SICKLE CELL DISEASE: A RETROSPECTIVE TIME SERIES ANALYSIS Sanjay Tewari PATER Received Received
  378-P MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL OF INTRAVENOUS ITRACONAZOLE VS. LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR HEMATOLOGICAL MALIGNANCY WITH PERSISTENT FEVER AND NEUTROPENIA Isao Yoshida PATER Received Received
  379-P PREVALENCE, STRUCTURE, AND PUTATIVE MECHANISM FOR TEMPLATED INSERTIONS IN VDJ RECOMBINATION Marvyn Koning PATER Received Received
  380-P FLUOROQUINOLONE PROPHYLAXIS SIGNIFICANTLY AFFECTS BACTERIAL EPIDEMIOLOLOGY AND ANTIBIOTIC RESISTANCE BUT DOES NOT IMPACT ON INCIDENCE AND MORTALITY OF BLOODSTREAM INFECTIONS IN ACUTE LEUKAEMIA Chiara CATTANEO PATER Received Received
  383-P INVASIVE FUNGAL INFECTIONS IN LYMPHOPROLIFERATIVE DISORDERS: REVISION OF INCIDENCE IN THE "MODERN TREATMENT" ERA Maria Chiara Tisi Received Received
  384-P INFECTIOUS AND THROMBOTIC COMPLICATIONS IN PERIPHERALLY INSERTED (PICCS) COMPARED TO SHORT TERM CENTRAL VENOUS CATHETERS IN ONCOHEMATOLOGIC PATIENTS: A REL GROUP (RETE EMATOLOGICA LOMBARDA) STUDY Nicola Stefano Fracchiolla Received Received
  385-P USEFULNESS OF SERUM 1,3-B-D-GLUCAN FOR DIAGNOSIS OF INVASIVE FUNGAL DISEASE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS Barbora Weinbergerova Fracchiolla Received Received
  386-P DIFFERENT ISOFORM LOCALIZATION GOVERNS SIGNALING QUALITY OF DECTIN-1 IN THE REGULATION OF ANTI-FUNGAL IMMUNITY Ulf Schnetzke Fracchiolla Received Received
  387-P PRELIMINARY REPORT OF FUNGEMIA IN HEMATOLOGICAL MALIGNANCIES FROM SEIFEM-2015 SURVEY Marianna Criscuolo Fracchiolla Received Received
  388-P PROGNOSTIC FACTORS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT: EXPERIENCE WITH 335 PATIENTS FROM A SINGLE CENTER Alfredo Rivas-Delgado Fracchiolla Received Received
  389-P SAFETY AND EFFICACY OF HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) HYPERIMMUNE GLOBULIN AGAINST HTLV-1 INFECTION IN A HUMANIZED MOUSE MODEL. Takuo Mizukami Fracchiolla Received Received
  391-P AUDIT OF TRANSFUSION PRACTICES IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION AT UNIVERSITY HOSPITALS BIRMINGHAM Aine BURKE Fracchiolla Received Received
  393-P IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) USE ON TRANSFUSION REQUIREMENTS AND BLOOD LOSS IN CARDIAC SURGERY Allison Mo Fracchiolla Received Received
  394-P COMBINED PLASMA EXCHANGE AND ERYTHROCYTAPHERESIS FOR TREATMENT OF MULTIORGAN FAILURE DUE TO SUSPECTED FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE Daniele Avenoso Fracchiolla Received Received
  396-P EFFECTS OF IMPLEMENTATION OF A MASSIVE TRANSFUSION PROTOCOL IN A TERTIARY REFERRAL HOSPITAL Ioannis Giannoutsos Fracchiolla Received Received
  397-P LOW PREVALENCE OF ALLOIMMUNIZATION AFTER RED BLOOD CELL TRANSFUSION IN 182 CHILDREN WITH SICKLE CELL DISEASE. Slimane Allali Fracchiolla Received Received
  402-P NEW MUTATION C.-140C>G IN 5´UTR OF ANKRD26 GENE IN PATIENTS WITH MILD FORM OF INHERITED THROMBOCYTOPENIA ASSOCIATED WITH MALIGNANCIES. Silvia FERRARI Fracchiolla Received Received
  403-P MYCHOFENOLATE MOFETILE FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME. A RESTROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEAMATOLOGY/ONCOLOGY GROUP Maurizio Miano Fracchiolla Received Received
  406-P THE IMMUNOMODULATORY EFFECTS OF RETINIC ACID IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA Qi Feng Received Received
  407-P STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL AND MCL PATIENTS TREATED WITH IBRUTINIB - PRELIMINARY RESULTS Darek Jawniak Vaccari Received Received
  408-P CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA CASES IN THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (ADULT) REGISTRY Indraraj Umesh Doobaree Received Received
  409-P EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT Sara Ali Doobaree Received Received
  410-P ORAL DIRECT ANTICOAGULANTS IN THE TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION. RESULTS OF THE DAILY CLINICAL PRACTICE Beatriz Perez Villardon Received Received
  411-P SWITCH FROM VKA, LMWH OR FONDAPARINUX TO DOACS IN THE CLINICAL PRACTICE. Francesco cortiula Villardon Received Received
  412-P HIGH HEMOGLOBIN CONCENTRATIONS AND RISK OF THROMBOSIS: CAUSALITY OR CONFOUNDING? Sæmundur Rögnvaldsson Villardon Received Received
  414-P ANNEXIN A5 M2 HAPLOTYPE: TO BE OR NOT TO BE, THAT´S THE QUESTION! Rita Tenreiro Villardon Received Received
  415-P IRON METABOLISM IN PATIENTS WITH PORTAL THROMBOSES Elena Lukina Villardon Received Received
  416-P PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER-RELATED VENOUS THROMBOSIS IN PATIENTS WITH HEMATOLOGICAL DISEASES Ana BOBAN Villardon Received Received
  417-P EQUATIONS FOR ESTIMATING GFR: COMPARING RENAL FUNCTION CATEGORISATION IN THE CATCH STUDY Mette Stagaard Janas Received Received
  418-P A PROSPECTIVE EVALUATION OF THE IMPACT OF TRANSFUSION DEPENDENCY ON QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES Francesco Sparano Janas Received Received
  422-P PATIENT PREFERENCES, SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT, ASSOCIATED BURDEN AND SIDE EFFECTS Carolin Buerkle Received Received
  423-P UNDERESTIMATED IMPACT OF MILD COGNITIVE IMPAIRMENT IN "CLINICALLY FIT" OLDER PATIENTS WITH MALIGNANT HEMOPATHIES ADMITTED TO RECEIVE CHEMOTHERAPY Dominique Bron Janas Received Received
  424-P WHAT DO PATIENT EXPERIENCE DATA REVEAL ABOUT THE DIAGNOSTIC JOURNEY FOR MYELOMA PATIENTS? FINDINGS FROM SECONDARY ANALYSIS OF NATIONAL CANCER PATIENT SURVEY DATA Sarah Richard Janas Received Received
  425-P STREAMLINING OF THE CHEMOTHERAPY SERVICE WITH FOCUS ON DRUG SUPPLY AND PATIENT SAFETY Heike Reinhardt Janas Received Received
  426-P INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA Ling-I HSU Janas Received Received
  526-P IN VIVO ROLE OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) EXPRESSION IN THE DEVELOPMENT OF PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Franziska Auer Received Received
  528-P THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA Giovanni Cazzaniga Janas Received Received
  529-P INSIGHTS INTO THE MOLECULAR EVOLUTION OF BCR-ABLP190 MEDIATED PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Franziska Auer Vaccari Received Received
  530-P THE ROLE OF CNOT3 AND THE ENTIRE CCR4-NOT COMPLEX IN TUMOR DEVELOPMENT Carmen VICENTE Received Received
  531-P CAPTURE-BASED NEXT GENERATION SEQUENCING (NGS) IDENTIFIES ALSO RARE IG/TCR REARRANGEMENTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS Marie Lorena Received Received
  532-P MIR-126 DRIVEN LEUKEMIA: A MURINE MODEL TO UNDERSTAND HUMAN B-ALL PATHOGENESIS Matteo Maria Received Received
  533-P MUTATIONS IN TP53 AND JAK2 GENES ARE ASSOCIATED WITH POOR PROGNOSIS IN PEDIATRIC AND ADULT PATIENTS WITH B-CELL PRECURSOR ALL Cristina Robledo Received Received
  536-P TARGETING BET FAMILY PROTEINS IMPROVES THE THERAPEUTIC EFFICACY OF BCL-2 INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Sofie PEIRS NALDINI Received Received
  538-P DELETIONS OF IKZF1 GENE, BUT NOT GENETIC RISK GROUPS, DEFINED BY COPY-NUMBER ALTERATIONS, ARE PROGNOSTICALLY SIGNIFICANT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ON ALL-MB 2008 PROTOCOL Grigory TSAUR NALDINI Received Received
  539-P LACK OF PROGNOSTIC SIGNIFICANCE OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE, B-CELL PRECURSOR ALL TREATED ACCORDING TO MRD-ORIENTED PROTOCOLS Josep Maria Received Received
  541-P PRELEUKEMIC CLONES IN NPM1-MUTATED AML MAY BE ASSOCIATED WITH EVOLUTION TO MYELODYSPLASTIC SYNDROME (MDS) OR MYELOPROLIFERATIVE NEOPLASM (MPN) Sarah morin Received Received
  542-P CLINICAL, HEMATOLOGICAL, BIOLOGIC AND MOLECULAR CHARACTERISTICS IN PATIENTS WHO DEVELOP ACUTE MYELOID LEUKEMIA FROM CHRONIC MYELOMONOCYTIC LEUKEMIA Temeida Alendar Ribera Received Received
  544-P SOMATIC DDX41 P.R525H MUTATION CAUSES GROWTH DEFECT IN HEMATOPOIETIC CELLS Hirotaka Matsui Received Received
  545-P WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN FAMILIAL MDS/AML Ana Rio-Machin Ribera Received Received
  547-P POOR PROGNOSIS MONOSOMIC AND TRISOMIC ACUTE MYELOID LEUKEMIA ASSOCIATES WITH CHECKPOINTS AND CDC20 DEREGULATION: A NOVEL LEUKEMOGENIC MECHANISM AND THERAPEUTIC TARGETS Giorgia Simonetti Ribera Received Received
  549-P PHYSIOPATHOLOGICAL MECHANISM OF LEUKEMIC PREDISPOSITION IN ANKRD26-RD PATIENTS Alessandro Donada Received Received
  550-P NOTCH SIGNALLING INHIBITION AS A MULTI-TARGET THERAPY TO OVERCOME BONE MARROW MICROENVIRONMENT-MEDIATED DRUG RESISTANCE IN AML Paul Takam Kamga Received Received
  552-P ENANTIOMER-SPECIFIC AND PARACRINE LEUKEMOGENICITY OF MUTANT IDH METABOLITE 2-HYDROXYGLUTARATE Anuhar Chaturvedi Received Received
  553-P INVOLVEMENT OF THE TRANSCRIPTION FACTOR ASCL2 IN NORMAL AND LEUKEMIC HEMATOPOIESIS Mallorie Dépond Kamga Received Received
  555-P IN VIVO SHRNA SCREEN IDENTIFIES SPLICING FACTOR RBM25 AS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA Ying Ge Received Received
  556-P HIGH MTORC1 ACTIVITY DRIVES GLUCOSE METABOLISM ADDICTION AND SENSITIVITY TO G6PD INHIBITION IN ACUTE MYELOID LEUKEMIA CELLS Laury Poulain Received Received
  559-P IDENTIFICATION OF A NOVEL STAT5 INHIBITOR TO INTERFERE WITH THE ONCOGENIC ACTIVITIES OF STAT5 IN AML Bettina Wingelhofer Received Received
  561-P DOUBLE INACTIVATION OF TET2 AND TET3 INDUCES HYPOMETHYLATING AGENT-SENSITIVE ACUTE MYELOID LEUKEMIA Koichiro Maie Kamga Received Received
  562-P NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE. Lynn Quek Kamga Received Received
  563-P HIGH PREDICTIVE VALUE OF COMBINED WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA Fabio Guolo Received Received
  565-P DNMT3A AND IDH1 MUTATIONS WORSEN THE PROGNOSIS OF ELN GOOD RISK (CEBPA OR NPM1 MUTATED/FLT3 UNMUTATED) AML PATIENTS Jana Marková Ribera Received Received
  567-P NANOG EXPRESSION AS A RESPONSIVE BIOMARKER DURING TREATMENT WITH HEDGEHOG SIGNAL INHIBITOR IN ACUTE MYELOID LEUKEMIA Seiji Kakiuchi Received Received
  569-P AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO FIRST LINE ACUTE MYELOID LEUKEMIA TREATMENT Ana Espinosa Received Received
  570-P RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA Shaun Fleming Kamga Received Received
  571-P CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+ AML) PATIENTS WITH INCREASED RISK OF RELAPSE. Anna Porwit Received Received
  575-P THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Giovanni Martinelli Received Received
  577-P PHARMACEUTICAL TARGETING OF PYRUVATE DEHYDROGENASE KINASES IN T(8;21) ACUTE MYELOID LEUKEMIA Hüsün Kizilkaya Kamga Received Received
  578-P HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS Chien-Chin Lin Received Received
  580-P LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) Sameer A. Parikh Received Received
  580-LB Mohamed Sorror Received Received
  581-P COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q DELETION Sara Raponi Received Received
  586-P IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPROLIFERATIVE DISORDERS Andy Rawstron Parikh Received Received
  587-P REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE Ilaria Del Giudice Received Received
  588-P PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS Zuzana Jaskova Giudice Received Received
  589-P PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT Andy Rawstron Received Received
  590-P THE SYK\JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA Andrew STEELE Received Received
  592-P IBRUTINIB FOR RELAPSED CLL PATIENTS OLDER THAN 75 YEARS: PROVEN EFFICACY, TOXICITIES TO KNOW Anne-Sophie MICHALLET Giudice Received Received
  595-P CHROMOSOME 8 ABNORMALITIES ARE ASSOCIATED WITH AN EVEN WORSE OUTCOME AND KARYOTYPE COMPLEXITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND TP53 ABERRATIONS Gonzalo Blanco Received Received
  598-P NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2 Panagiotis Baliakas Giudice Received Received
  601-P ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML Stefania Rocca Received Received
  602-P A NOVEL C-TERMINAL HSP90 INHIBITOR WITH THERAPEUTIC EFFECT IN IMATINIB RESISTANT CML. Sanil Bhatia Ribera Received Received
  604-P MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA Ilaria Stefania Pagani Received Received
  605-P CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA Dimitrios Karamitros Pagani Received Received
  606-P ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS Manuela Mancini Pagani Received Received
  610-P THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA Lucy Fox Pagani Received Received
  611-P THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA Sara Galimberti Pagani Received Received
  612-P REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML Mario Tiribelli Pagani Received Received
  613-P FACTORS THAT INFLUENCE PATIENT WILLINGNESS TO ATTEMPT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA David Ross Pagani Received Received
  614-P GENETIC VARIABILITY OF OXIDATIVE STRESS AND DNA REPAIR GENES – POTENTIAL PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN CHRONIC MYELOID LEUKEMIA Ana Cristina Gonçalves Received Received
  616-P BCR-ABL1 TRANSCRIPT LEVEL ON DAY+28 CAN PREDICT EARLY MOLECULAR RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO TREATED WITH FRONTLINE DASATINIB Won Sik LEE Received Received
  619-P IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA Alessandra Freyrie Gonçalves Received Received
  620-P AGE DISTRIBUTION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN GERMANY AND THEIR PROGNOSIS ACCORDING TO THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS): DATA FROM THE REGULAR CARE MDS REGISTRY H Tilman Steinmetz Received Received
  621-P VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER Daniel Moreno Berggren Received Received
  622-P EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH OR WITHOUT EVOLUTION TO LEUKEMIA Yan MA Berggren Received Received
  623-P HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY. Bastida Jose Maria Received Received
  625-P CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014 Avinash Dinmohamed Maria Received Received
  626-P LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES Amy DeZern Maria Received Received
  627-P THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION OF PATIENTS WITH LOWER-RISK MDS. Teresa Knight Asorey Received Received
  628-P STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION Nataliya PETINATI Received Received
  629-P SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY? Eva-Stina Kairemo Asorey Received Received
  632-P A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495, A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Jeffrey Johnston Asorey Received Received
  633-P THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC ANEMIA (AA) PATIENTS. Thomas Nevill Asorey Received Received
  638-P IKAROS PROTEIN EXPRESSION IN BONE MARROW B AND T CELLS RATHER THAN MYELOMA CELLS PREDICTS OUTCOME AFTER LENALIDOMIDE-DEXAMETHASONE THERAPY Arnold Bolomsky Asorey Received Received
  639-P CXCL13 CHEMOKINE – A NOVEL TARGET IN MULTIPLE MYELOMA MICROENVIRONMENT Katia BEIDER Asorey Received Received
  640-P MESENCHYMAL STEM CELLS (MSC) PROMOTES TUMOR MICROENVIRONMENT TRANSFORMATION DRIVING GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ACTIVATION IN SMOLDERING AND MULTIPLE MYELOMA PATIENTS Daniele Tibullo Asorey Received Received
  641-P TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH & SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT Arnold Bolomsky Asorey Received Received
  642-P LENALIDOMIDE MAINTENANCE COUNTERACTS PD-1 ELEVATION ON LYMPHOCYTES IN MYELOMA PATIENTS Sophia Danhof Maria Received Received
  643-P CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS Fedor Kryukov Received Received
  644-P PRECLINICAL EVALUATION OF ABBV-838, A FIRST-IN-CLASS ANTI-CS1 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF MULTIPLE MYELOMA Kurt Gish Asorey Received Received
  648-P PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA Tyce Havens Received Received
  650-P OUTCOME OF MYELOMA PATIENTS WITH DELETION 17P – IMPACT OF BASELINE CHARACTERISTICS, TREATMENT AND ADDITIONAL CHROMOSOMAL CHANGES Maximilian Merz Received Received
  651-P CIRCULATING TUMOR DNA IN MULTIPLE MYELOMA Even Holth Rustad Received Received
  654-P PROSPECTIVE COMORBIDITY AND FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA) IN MULTIPLE MYELOMA (MM) PATIENTS (PTS): RESULTS FROM A MULTICENTER GERMAN STUDY GROUP MM (DSMM) TRIAL Sandra Dold Rustad Received Received
  657-P PROSPECTIVE EVALUATION OF GERIATRIC ASSESSMENT TOOLS IN REAL-WORLD, UNSELECTED, ELDERLY PATIENTS WITH SYMPTOMATIC MYELOMA Efstathios Kastritis Received Received
  665-P PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND STANDARD-RISK CYTOGENETICS Moritz Binder Received Received
  666-P CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE Georgia METZGEROTH Rustad Received Received
  667-P THROMBOTIC RISK IN IDIOPATHIC ERYTHROCYTOSIS IS LOWER THAN IN POLYCYTHEMIA VERA BUT HIGHER THAN IN GENERAL POPULATION. Maria Luigia Randi Received Received
  669-P COMPARISON OF GENOMIC DNA-BASED VS. MESSENGER RNA-BASED KIT D816V MUTATION ANALYSIS REVEALS LARGE DIFFERENCES BETWEEN BLOOD AND BONE MARROW IN SYSTEMIC MASTOCYTOSIS Thomas Kristensen Randi Received Received
  670-P 3167 NEWLY DIAGNOSED MPN PATIENTS, A REPORT FROM THE SWEDISH MPN REGISTRY Björn Andreasson Randi Received Received
  671-P PREDICTIVE ROLE OF CIRCULATING LEUCOCYTE-PLATELET AGGREGATES FOR THROMBOEMBOLIC COMPLICATIONS IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A PROSPECTIVE STUDY Dijana Šefer Received Received
  672-P PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS Nicola Polverelli Received Received
  676-P PROGNOSTIC IMPACT OF INTEGRATED GENOMIC PROFILING IN ADULT T-CELL LEUKEMIA/LYMPHOMA Keisuke Kataoka Received Received
  677-P HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET Miguel Gallardo Randi Received Received
  678-P GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE. Shamzah Araf Randi Received Received
  679-P SOMATIC MUTATION PROFILING FOR PROGNOSIS AND TREATMENT STRATIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE REMODL-B TRIAL Ming Qing Du Received Received
  680-P ADHESION MOLECULE JAM-C: A POTENTIAL TARGET FOR MANTLE CELL LYMPHOMA THERAPEUTICS Thomas Matthes Randi Received Received
  681-P ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL LYMPHOMA BUT DO NOT IMPACT PATIENTS´ SURVIVAL Andrea MARECKOVÁ Randi Received Received
  683-P TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONE ITALIANA LINFOMI (FIL) Simone Ferrero Received Received
  684-P DECIPHERING THE IMPACT OF IDELALISIB ON FOLLICULAR LYMPHOMA AND ITS IMMUNE MICROENVIRONMENT Patricia Pérez-Galán Randi Received Received
  685-P MIR-34A PREVENTS LUNG INJURY IN BLEOMYCIN INDUCED PULMONARY FIBROSIS Raanan Bulvik Du Received Received
  686-P INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA Rumiko Kanzaki Randi Received Received
  687-P PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL Laura Magnano Randi Received Received
  688-P DISTINCT INCREASING TREND AND BIRTH-COHORT EFFECT OF FOLLICULAR LYMPHOMA INCIDENCE IN TAIWAN: EPIDEMIOLOGICAL ANALYSES AND IMPLICATIONS Shang-Ju Wu Received Received
  689-P LONG-TERM OUTCOMES OF 131I-RITUXIMAB RADIOIMMUNOTHERAPY IN FOLLICULAR NON-HODGKIN LYMPHOMA: TEN YEAR UPDATE ON TOXICITY, TIME-TO-NEXT-TREATMENT AND SURVIVIAL OF THE PHASE II INITIAL STUDY Murali Kesavan Received Received
  690-P LONG TERM OUTCOMES IN PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS (POAML): A LARGE SINGLE INSTITUTE COHORT STUDY. Amrita Desai Received Received
  691-P EARLY TRANSFORMATION IN LOW-GRADE LYMPHOMAS AND ITS ADVERSE PROGNOSTIC SIGNIFICANCE ON SURVIVAL Luis Miguel Juárez Received Received
  692-P OFATUMOMAB FOR THE TREATMENT OF EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA): THE O-MA1 STUDY Barbara Kiesewetter Received Received
  694-P FINAL RESULTS OF IHC ANALYSIS AND PROGNOSTIC FACTORS IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION Manali Kamdar Juárez Received Received
  695-P IMPROVED OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH PRESERVATION OF COGNITIVE FUNCTION Shireen Kassam Juárez Received Received
  697-P NONPEGHYLATED LIPOSOMAL DOXORUBICIN AS A COMPONENT OF R-CHOP IS EFFECTIVE AND SAFE IN THE TREATMENT OF A CARDIAC HIGH-RISK AND ELDERLY LYMPHOMA PATIENTS Luigi Rigacci Juárez Received Received
  698-P METHYLATION OF CELL-FREE CIRCULATING DNA IN PLASMA PREDICTS POOR OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA Lasse Sommer Received Received
  701-P DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: REAL LIFE ANALYSIS OF PATIENTS WITH REFRACTORY DISEASE OR RELAPSE Bente Arboe Kristensen Received Received
  702-P CENTRAL NERVOUS SYSTEM INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL LYMPHOMA Naoto Tomita Kristensen Received Received
  704-P DETECTION OF BONE MARROW INVOLVEMENT OF DLBCL - COMPARISON OF PET-CT AND BONE MARROW BIOPSY Yuki Nakajima Received Received
  707-P A NOVEL QUANTITATIVE PCR APPROACH TARGETING INSERTION/DELETION POLYMORPHISMS (INDEL-PCR) FOR CHIMERISM QUANTIFICATION: FINALLY HIGH SENSITIVITY AND QUANTIFICATION CAPACITY TOGETHER Almudena Navarro-Bailón Kristensen Received Received
  708-P A NEW APPROACH OF DUAL-SCT WITH UNMANIPULATED HAPLO-IDENTICAL GRAFT AND UNRELATED CORD BLOOD IN PATIENTS WITH HEMATOLOGICAL DISORDERS Depei Wu Kristensen Received Received
  709-P RECIPIENT CCR5 GENETIC VARIATION PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED DONOR BONE MARROW TRANSPLANTATION. Tomohiro Horio Kristensen Received Received
  710-P PRESUMABLY FALSE POSITIVE MINIMAL RESIDUAL DISEASE (MRD) QPCR RESULTS AFTER ALLOGENEIC SCT UNCOVERED BY NEXT GENERATION SEQUENCING (NGS) Michaela Kotrová Kristensen Received Received
  711-P PRE-EMPTIVE THERAPY WITH IFN-?-2B FOR ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT Depei Wu Kristensen Received Received
  712-P A STUDY OF RHTPO IN COMBINATION WITH CHEMOTHERAPY AND G-CSF FOR PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA Haitao Bai Kristensen Received Received
  713-P A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION Inge JEDEMA Kristensen Received Received
  714-P WHICH CONDITIONING REGIMEN IS MORE EFFECTIVE FOR HIGH-RISK PATIENTS WITH AML/MDS : COMPARING LOW-DOSE DECITABINE COMBINED WITH MODIFIED BUCY WITH MODIFIED BUCY FOLLOWED BY ALLO-HSCT Depei Wu Kristensen Received Received
  715-P ELEVATED EXPRESSION OF TIM-3 ON CD8 T CELLS CORRELATES WITH CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENIC STEM CELL TRANSPLANTATION Depei Wu Kristensen Received Received
  716-P INTERFERON-GAMMA GENE POLYMORPHISM ASSOCIATE WITH MORTALITY AND GRAFT-VERSUS-HOST DISEASE SEVERITY IN HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION Maria Virginia Received Received
  718-P BASELINE LABORATORY VARIABLES SERVE AS POTENT PREDICTORS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RELATED MORTALITY Roni SHOUVAL Received Received
  720-P COMPARING TIME-DEPENDENT PREDICTIVE PERFORMANCE OF ALLOGENEIC HSCT RISK SCORING SYSTEMS Joshua Fein Palau Received Received
  721-P PROPHYLACTIC DLI VS NO DLI FOR REFRACTORY ACUTE LEUKEMIA UNDERGOING ALLO-HSCT WITH SEQUENTIAL INTENSIFIED CONDITIONING Qifa Liu Palau Received Received
  722-P THE PRE-TRANSPLANT BIOMARKER RISK INDEX BASED ON SERUM FERRITIN, ALBUMIN AND CRP CAN PREDICT OUTCOMES INDEPENDENTLY OF THE HCT-CI AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Tatsuya Suwabe Palau Received Received
  723-P HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA Shuning Zuo Palau Received Received
  725-P MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE GUIDED SEQUENTIAL CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION COULD IMPROVE SURVIVAL OF PATIENTS WITH ACUTE LEUKEMIA WHO RELAPSED AFTER ALLO-HSCT Chen Hua Yan Received Received
  727-P BIFURCATION INTO HEMATOPOIETIC STEM CELL TYPES IS DEPENDENT UPON THE DEVELOPMENTAL SIGNALING MOLECULES Mihaela CRISAN Palau Received Received
  728-P LACK OF MIR-127 DOWN-REGULATION IN THE TRANSITION FROM HEMATOPOIETIC STEM CELLS TO MULTI-POTENT PROGENITORS LEADS TO PANCYTOPENIA AND DEFECTIVE SELF-RENEWAL Francesca Ficara Palau Received Received
  729-P NAMPT-NAD+-SIRT2 PATHWAY-TRIGGERED DEACETYLATION OF LMO2 PROTEIN IS INDISPENSABLE IN THE EARLY HEMATOPOIESIS THROUGH COMPLETE TAL1 COMPLEX FORMATION Tatsuya Morishima Received Received
  731-P EXPRESSION OF BCL2, BUT NOT STAT5 SIGNALING, RESCUES LYMPHOPOIESIS IN THE ABSENCE OF HHEX Jacob T Received Received
  732-P ANAMORSIN IS ESSENTIAL FOR B-CELL TERMINAL DIFFERENTIATION Yuri Hamanaka Received Received
  733-P DOWNREGULATION OF CD44 FUNCTIONALLY DEFINES HUMAN T-CELL COMMITMENT Kirsten Canté-Barrett Received Received
  734-P KNOCKDOWN OF THE ADHESION G-PROTEIN COUPLED RECEPTOR 56 IMPAIRS HUMAN CORD BLOOD STEM AND PROGENITOR CELL FUNCTION Lixiazi He Palau Received Received
  735-P DISSECTING THE ROLE OF THE MICROENVIRONMENT IN APLASTIC ANEMIA USING AN IN VIVO HAEMATOPOIETIC STEM CELL NICHE MODEL Ilaria Marina Michelozzi Received Received
  737-P EFFICIENT GENOME EDITING OF MOUSE HEMATOPOIETIC CELLS USING CRISPR/CAS9 TECHNOLOGY Evgenia Sarrou Received Received
  738-P COMPREHENSIVE PROTEOMIC ANALYSIS OF HUMAN ERYTHROPOIESIS Emilie-Fleur GAUTIER Received Received
  740-P STAPHYLOCOCCUS AUREUS PROTEIN ISDH INHIBITS THE CD163 PATHWAY FOR HAPTOGLOBIN-FACILITATED HEMOGLOBIN SCAVENGING Kirstine Lindhardt Madsen Received Received
  742-P AG-519 IS A POTENT ACTIVATOR OF MUTANT PYRUVATE KINASE ASSOCIATED WITH HEMOLYTIC ANEMIA Charles Kung Madsen Received Received
  743-P REDPLEX: A TARGETED NEXT GENERATION SEQUENCING-BASED DIAGNOSIS FOR PATIENTS WITH HEREDITARY HEMOLYTIC ANEMIAS Roberta Russo Madsen Received Received
  745-P ELEVATED PLASMA ASYMMETRIC DIMETHYLARGININE LEVELS IN CHILDREN WITH BETA-THALASSEMIA MAJOR MAY BE AN EARLY MARKER FOR ENDOTHELIAL DYSFUNCTION Orhan GURSEL Madsen Received Received
  747-P PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING PRACTICE FROM UK CENTRES: A REPORT FROM THE UK PNH NETWORK Morag griffin Michelozzi Received Received
  748-P DIAGNOSTIC VALUES FOR IRON DEFICIENCY ANEMIA IN CHILDREN AND WOMEN USING SERUM HEPCIDIN AND ZINC PROTOPORPHYRIN (ZPP) Giridhar Kanuri Madsen Received Received
  749-P UTILITY OF RED CELL INDICES TO DIAGNOSE IRON DEFICIENCY IN RURAL INDIAN CHILDREN Swaratika majumdar Madsen Received Received
  751-P SEARCH AND YOU SHALL FIND – VARIANT HEMOCHROMATOSIS GENE MUTATIONS AS A CAUSE OF HYPERFERRITINEMIA IN BLOOD DONORS Adam Høgsbro Received Received
  752-P A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG-519, AN ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R IN HEALTHY SUBJECTS Ann Barbier Received Received
  753-P ANALYSIS OF MOLECULAR MECHANISMS OF DOMINANT-INTERFERING FAS MUTATIONS Daniel Schäfer Laursen Received Received
  754-P UNSMAKING PRIMARY IMMUNE DEFICIENCIES IN EARLY-ONSET EVANS SYNDROME USING IMMUNOPHENOTYPING AND NGS: TOWARDS A CLINICAL AND GENETIC CLASSIFICATION Nathalie Aladjidi Laursen Received Received
  755-P MRI SKELETAL MANIFESTATIONS IN GAUCHER DISEASE: UTILITY OF SPANISH-MRI (S-MRI) SCORE AT DIAGNOSIS AND FOLLOW-UP Marcio Andrade-Campos Laursen Received Received
  756-P SEVUPARIN DEMONSTRATES BINDING TO KEY ADHESION RECEPTORS INVOLVED IN PATHOGENESIS OF SICKLE CELL DISEASE Maria Lindgren Laursen Received Received
  757-P GLUTATHIONE S TRANSFERASE GENE POLYMORPHISMS AND THE RISK OF CNS COMPLICATIONS OF SICKLE CELL DISEASE IN EGYPTIAN PATIENTS Hend Ellithy Michelozzi Received Received
  760-P INCREASED LEVELS OF CIRCULATING IMMATURE GRANULOCYTES IN SEPSIS HAVE A SIGNIFICANT IMPACT ON SURVIVAL: RESULTS OF THE FRENCH MULTICENTRIC SEPTIFLUX 2 STUDY Estelle GUERIN Laursen Received Received
  761-P USEFULNESS OF A THIRTY ONE-GENE PANEL BY NEXT-GENERATION SEQUENCING FOR THE MOLECULAR DIAGNOSTIC OF INHERITED BLEEDING COAGULATION DISORDERS Jose Maria BASTIDA Received Received
  762-P APPLICATION OF A MOLECULAR DIAGNOSTIC ALGORITHM FOR HEMOPHILIA A AND B USING NEXT-GENERATION SEQUENCING OF THE WHOLE F8, F9 AND VWF GENES. Bastida Jose Received Received
  763-P ASSAY DISCREPANCY IN MILD HAEMOPHILIA A PATIENTS WITH MUTATIONS IN FVIII A DOMAIN Alenka Trampuš Bakija Received Received
  764-P ARTHROPATHY IN PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE Karin van Galen Received Received
  765-P A COMPREHENSIVE NEXT GENERATION SEQUENCING TEST FOR THE DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET DISORDERS Suthesh Sivapalaratnam Galen Received Received
  766-P THE ROLE OF CD72 IN THE REGULATION OF B CELL ACTIVATION THROUGH CD40 IN PRIMARY IMMUNE THROMBOCYTOPENIA Mingen Lyu Received Received
  768-P QUALITATIVE AND QUANTITATIVE ANALYSIS OF INTRAHEPATIC BLOOD FLOW CHANGES IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) Roland Schelker BASTIDA Received Received
  771-P RECOMBINANT THROMBOMODULIN AMELIORATES HEMATOLOGICAL MALIGNANCY-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION MORE PROMPTLY THAN CONVENTIONAL THERAPY WITHOUT CAUSING SEVERE HEMORRHAGIC EVENTS Naoki Kurita Galen Received Received
  772-P EXTRACELLULAR HISTONES ENHANCE FACTOR XA MEDIATED PROTHROMBIN ACTIVATION WITHOUT PHOSPHOLIPID REQUIREMENT Yasmina Sahraoui Galen Received Received
  773-P PHORBOL 12-MYRISTATE-13-ACETATE INDUCES VON WILLEBRAND FACTOR PROPEPTIDE RELEASE FROM ENDOTHELIAL CELLS FROM 2 DISTINCT COMPARTMENTS Ruben Bierings Galen Received Received
  774-P NEWLY DIAGNOSED PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH ENHANCED TF PATHWAY ACTIVATION, THROMBIN GENERATION AND INCREASED CONCENTRATION OF PROCOAGULANT MICROPARTICLES Despoina Fotiou BASTIDA Received Received
  775-P ROLE OF ROTATIONAL THROMBELASTOMETRY (ROTEM®) IN RAPID ESTIMATION OF RIVAROXABAN DRUG LEVEL Hun Chuah Galen Received Received
  778-P INCIDENCE OF PERIPHERAL CIRCULATING CELLS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PHENOTYPE A FIRST EPISODE OF CEREBRAL SINUS VEIN THROMBOSIS: RESULTS FROM A PROSPECTIVE MULTICENTER STUDY Mariasanta Napolitano Received Received
  779-P REGULATION OF WEIBEL-PALADE BODY EXOCYTOSIS FROM ENDOTHELIAL CELLS BY SYNTAXIN-3 AND STXBP5 CONTAINING SNARE COMPLEXES. Ruben Bierings Received Received
  780-P COMPARISON OF QUALITY OF LIFE BETWEEN LONG-TERM SURVIVORS OF INDOLENT AND AGGRESSIVE LYMPHOMA: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY Seok Jin Kim Received Received
  781-P IMPACT OF IRON DEFICIENCY ON QUALITY OF LIFE AND WORK CAPACITY OF WOMEN Lucilia Caramelo Kim Received Received
  782-P IRON DEFICIENCY: UNDERSTANDING PERCEPTIONS OF SUFFERERS AND THE GENERAL PUBLIC Lucilia Caramelo Kim Received Received
  784-P THE RELATIVE BURDEN OF AL AMYLOIDOSIS ON HEALTH-RELATED QUALITY OF LIFE Kristen L. McCausland Received Received
  785-P OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA IN A LARGE COHORT INSIDE A PHASE 1 CLINIC DEPARTMENT. Jean-Marie Michot McCausland Received Received
  787-P HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN LONGITUDINAL STUDIES INCLUDING MULTIPLE MYELOMA PATIENTS: A CRITICAL REVIEW OF INTERPRETING CHANGES OF SCORES OBTAINED BY EORTC QLQ-C30 Lene Kongsgaard Nielsen Received Received
  2239-LB Giovanni Cazzaniga Received Received
  2242-LB David Britton Received Received
  2244-LB Claudio Cerchione Received Received
  2249-LB Jeffrey Johnston Received Received
  2251-LB Rainer Hubmann Received Received
  2253-LB K. Byrgazov Received Received
  2255-LB Giovanni Caocci Received Received
  2258-LB Claudio Cerchione Received Received
  2264-LB Monika Klimkowska Received Received
  2266-LB Yohei Kanamori Received Received
  2268-LB S. Ekwattanakit Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
09:00
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN HEMATOLOGY ASSOCIATION

21st Congress of EHA

 

June 9th - June 12th 2016 Copenhagen
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 10/06/2016 TO 10/06/2016
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.21EHA.2016 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 26/05/2016
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster







PosterSessionOnline
Logo Draft
 
Logo Cert